Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 3/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 3/20 | 0.51 |
| ▸ | CTSG | P08311 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14009929 | 0.88 | LMNA (0.50) | LMNAELANEPRTN3CTSGALDH1A1 | |
| Ethadione SCHEMBL35279 | 0.83 | ELANE (0.55) | LMNAELANEPRTN3CTSGAR | |
| SCHEMBL13188868 | 0.82 | LMNA (0.52) | LMNAELANEPRTN3CTSGAR | |
| SCHEMBL5006337 | 0.82 | ELANE (0.54) | LMNAELANEPRTN3CTSGAR | |
| SCHEMBL4756222 | 0.82 | LMNA (0.52) | LMNAELANEPRTN3CTSGAR | |
| Hydrochloric Acid SCHEMBL3149437 | 0.80 | LMNA (0.50) | LMNAELANEPRTN3CTSGAR | |
| SCHEMBL4757604 | 0.79 | LMNA (0.48) | LMNAELANEPRTN3CTSGAR | |
| Ethadione SCHEMBL13724326 | 0.79 | LMNA (0.70) | LMNAELANEPRTN3CTSGAR | |
| SCHEMBL5005434 | 0.79 | ELANE (0.51) | LMNAELANEPRTN3CTSGAR | |
| SCHEMBL14009888 | 0.77 | LMNA (0.47) | LMNAELANEPRTN3CTSGAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | LMNA 4742/4885ELANE 4068/4885PRTN3 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.